The report covers a forecast and an analysis of the overactive bladder treatment market on a global and regional level. The study provides historical data from 2016 to 2018 along with a forecast from 2019 to 2025 based on revenue (USD Million). The study includes drivers and restraints of the overactive bladder treatment market along with their impact on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the overactive bladder treatment market on a global level.
In order to give the users a comprehensive view of the overactive bladder treatment market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.
The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on a global and regional basis.
The study provides a decisive view of the overactive bladder treatment market by segmenting it based on pharmacotherapy, disease, and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2025. The regional segment includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
Some major players involved in the overactive bladder treatment market are Macleods Pharmaceuticals, Allergan, Mylan, Endo International, Sanofi, Apotex, Johnson & Johnson, Aurobindo Pharma, Medtronic, Cogentix Medical, Astellas Pharma, Pfizer, Teva Pharmaceutical, Hisamitsu Pharmaceutical, and Intas Pharmaceuticals.
This report segments the global overactive bladder treatment market into:
Global Overactive Bladder Treatment Market: Pharmacotherapy Analysis
Global Overactive Bladder Treatment Market: Disease Analysis
In order to give the users a comprehensive view of the overactive bladder treatment market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.
The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on a global and regional basis.
The study provides a decisive view of the overactive bladder treatment market by segmenting it based on pharmacotherapy, disease, and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2025. The regional segment includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
Some major players involved in the overactive bladder treatment market are Macleods Pharmaceuticals, Allergan, Mylan, Endo International, Sanofi, Apotex, Johnson & Johnson, Aurobindo Pharma, Medtronic, Cogentix Medical, Astellas Pharma, Pfizer, Teva Pharmaceutical, Hisamitsu Pharmaceutical, and Intas Pharmaceuticals.
This report segments the global overactive bladder treatment market into:
Global Overactive Bladder Treatment Market: Pharmacotherapy Analysis
- Botox
- Anticholinergic
- Others
Global Overactive Bladder Treatment Market: Disease Analysis
- Idiopathic Overactive Bladder
- Neurogenic Overactive Bladder
- Overactive Bladder in Stroke
- Parkinson’s Disease
- Overactive Bladder in Multiple Sclerosis
- Overactive Bladder in Spinal Cord
- Overactive Bladder in Other Disorders
- North America
- The U.S.
- Europe
- UK
- France
- Germany
- Asia Pacific
- China
- Japan
- India
- Latin America
- Brazil
- Middle East and Africa
Table of Contents
- Chapter 1. Preface
- 1.1. Report Description and Scope
- 1.2. Research Scope
- 1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology
- Chapter 2. Executive Summary
- 2.1. Overactive bladder treatment Market, 2016-2025 (USD Million)
- 2.2. Overactive bladder treatment Market: Market Snapshot
- Chapter 3. Overactive Bladder Treatment Market - Industry Analysis
- 3.1. Overactive Bladder Treatment Market: Dynamics
- 3.2. Market Drivers
- 3.2.1. Growing prevalence of overactive bladder
- 3.2.2. Growing geriatric population
- 3.2.3. Rising neurological disorders
- 3.2.4. Increasing government initiatives and awareness in developing nations
- 3.2.5. Advanced R&D in the field of overactive bladder treatment
- 3.2.6. Rising acute urinary tract infection cases
- 3.3. Restraints
- 3.3.1. Lack of awareness in underdeveloped nations
- 3.3.2. Undesirable effects of current treatments
- 3.4. Opportunity
- 3.4.1. Evolving market
- 3.4.2. Advanced technology
- 3.5. Porter's Five Forces Analysis
- 3.6. Market Attractiveness Analysis
- 3.6.1. Market attractiveness analysis by pharmacotherapy
- 3.6.2. Market attractiveness analysis by disease
- 3.6.3. Market attractiveness analysis by region
- Chapter 4. Overactive Bladder Treatment Market - Competitive Landscape
- 4.1. Company market share analysis
- 4.1.1. Global overactive bladder treatment market: company market share, 2018
- 4.2. Strategic development
- 4.2.1. Acquisitions & mergers
- 4.2.2. New product launches
- 4.2.3. Agreements, partnerships, collaborations, and joint ventures
- 4.2.4. Research and development and regional expansion
- 4.3. Price trend analysis
- 4.1. Company market share analysis
- Chapter 5. Global Overactive Bladder Treatment Market - Pharmacotherapy Analysis
- 5.1. Global overactive bladder treatment market overview: by pharmacotherapy
- 5.1.1. Global overactive bladder treatment market share, by pharmacotherapy, 2018 and 2025
- 5.2. Botox
- 5.2.1. Global overactive bladder treatment market by botox, 2016-2025 (USD Million)
- 5.3. Anticholinergic
- 5.3.1. Global overactive bladder treatment market by anticholinergic, 2016-2025 (USD Million)
- 5.4. Others
- 5.4.1. Global overactive bladder treatment market by others, 2016-2025 (USD Million)
- 5.1. Global overactive bladder treatment market overview: by pharmacotherapy
- Chapter 6. Global Overactive Bladder Treatment Market - Disease Analysis
- 6.1. Global overactive bladder treatment market overview: by disease
- 6.1.1. Global overactive bladder treatment market share, by disease, 2018 and 2025
- 6.2. Idiopathic Overactive Bladder
- 6.2.1. Global overactive bladder treatment market by idiopathic overactive bladder, 2016-2025 (USD Million)
- 6.3. Neurogenic Overactive Bladder
- 6.3.1. Global overactive bladder treatment market by neurogenic overactive bladder, 2016-2025 (USD Million)
- 6.1. Global overactive bladder treatment market overview: by disease
- Chapter 7. Global Overactive Bladder Treatment Market - Regional Analysis
- 7.1. Global overactive bladder treatment market overview: by region
- 7.1.1. Global overactive bladder treatment market share, by region, 2018 and 2025
- 7.2. North America
- 7.2.1. North America overactive bladder treatment market, 2016-2025 (USD Million)
- 7.2.2. North America overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
- 7.2.3. North America overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
- 7.2.4. The U.S.
- 7.2.4.1. The U.S. overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
- 7.2.4.2. The U.S. overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
- 7.2.5. Rest of North America
- 7.2.5.1. Rest of North America overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
- 7.2.5.2. Rest of North America overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
- 7.3. Europe
- 7.3.1. Europe overactive bladder treatment market, 2016-2025 (USD Million)
- 7.3.2. Europe overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
- 7.3.3. Europe overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
- 7.3.4. The U.K.
- 7.3.4.1. U.K. overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
- 7.3.4.2. U.K. overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
- 7.3.5. France
- 7.3.5.1. France overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
- 7.3.5.2. France overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
- 7.3.6. Germany
- 7.3.6.1. Germany overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
- 7.3.6.2. Germany overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
- 7.3.7. Rest of Europe
- 7.3.7.1. Rest of Europe overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
- 7.3.7.2. Rest of Europe overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
- 7.4. Asia Pacific
- 7.4.1. Asia Pacific overactive bladder treatment market, 2016-2025 (USD Million)
- 7.4.2. Asia Pacific overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
- 7.4.3. Asia Pacific overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
- 7.4.4. China
- 7.4.4.1. China overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
- 7.4.4.2. China overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
- 7.4.5. Japan
- 7.4.5.1. Japan overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
- 7.4.5.2. Japan overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
- 7.4.6. India
- 7.4.6.1. India overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
- 7.4.6.2. India overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
- 7.4.7. Rest of Asia Pacific
- 7.4.7.1. Rest of Asia Pacific overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
- 7.4.7.2. Rest of Asia Pacific overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
- 7.5. Latin America
- 7.5.1. Latin America overactive bladder treatment market, 2016-2025 (USD Million)
- 7.5.2. Latin America overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
- 7.5.3. Latin America overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
- 7.5.4. Brazil
- 7.5.4.1. Brazil overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
- 7.5.4.2. Brazil overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
- 7.5.5. Rest of Latin America
- 7.5.5.1. Rest of Latin America overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
- 7.5.5.2. Rest of Latin America overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
- 7.6. The Middle East and Africa
- 7.6.1. The Middle East and Africa overactive bladder treatment market, 2016-2025 (USD Million)
- 7.6.2. The Middle East and Africa overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
- 7.6.3. The Middle East and Africa overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
- 7.1. Global overactive bladder treatment market overview: by region
- Chapter 8. Company Profiles
- 8.1. Macleods Pharmaceuticals
- 8.1.1. Overview
- 8.1.2. Financials
- 8.1.3. Product Portfolio
- 8.1.4. Business Strategy
- 8.1.5. Recent Developments
- 8.2. Allergan
- 8.2.1. overview
- 8.2.2. Financials
- 8.2.3. Product Portfolio
- 8.2.4. Business Strategy
- 8.2.5. Recent Developments
- 8.3. Mylan
- 8.3.1. Overview
- 8.3.2. Financials
- 8.3.3. Product Portfolio
- 8.3.4. Business Strategy
- 8.3.5. Recent Developments
- 8.4. Endo International
- 8.4.1. Overview
- 8.4.2. Financials
- 8.4.3. Product Portfolio
- 8.4.4. Business Strategy
- 8.4.5. Recent Developments
- 8.5. Hisamitsu Pharmaceutical
- 8.5.1. Overview
- 8.5.2. Financials
- 8.5.3. Product Portfolio
- 8.5.4. Business Strategy
- 8.5.5. Recent Developments
- 8.6. Apotex
- 8.6.1. Overview
- 8.6.2. Financials
- 8.6.3. Product Portfolio
- 8.6.4. Business Strategy
- 8.6.5. Recent Developments
- 8.7. Johnson & Johnson
- 8.7.1. Overview
- 8.7.2. Financials
- 8.7.3. Product Portfolio
- 8.7.4. Business Strategy
- 8.7.5. Recent Developments
- 8.8. Aurobindo Pharma
- 8.8.1. Overview
- 8.8.2. Financials
- 8.8.3. Product Portfolio
- 8.8.4. Business Strategy
- 8.8.5. Recent Developments
- 8.9. Medtronic
- 8.9.1. Overview
- 8.9.2. Financials
- 8.9.3. Product Portfolio
- 8.9.4. Business Strategy
- 8.9.5. Recent Developments
- 8.10. Cogentix Medical
- 8.10.1. Overview
- 8.10.2. Financials
- 8.10.3. Product Portfolio
- 8.10.4. Business Strategy
- 8.10.5. Recent Developments
- 8.1. Macleods Pharmaceuticals
